---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-019257"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T03:57:38.502353+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CytomX CBO Jeffrey Landau to depart effective Feb 7, 2025

## Summary
- Jeffrey Landau, SVP, Chief Business Officer, and Head of Strategy, will leave the company on February 7, 2025.
- Separation agreement provides economic payments consistent with existing severance and change of control agreement.
- Separation includes a general release of claims against the company.
- No replacement for Landau's role has been announced.

## SEC filing metadata
- accession: 0001193125-25-019257
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312525019257/0001193125-25-019257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312525019257/d924316d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-019257
- JSON: https://secwatch.observer/filing/0001193125-25-019257.json
- Plain text: https://secwatch.observer/filing/0001193125-25-019257.txt

## Key facts
- Executive change
  Jeffrey Landau was terminated as Senior Vice President, Chief Business Officer, and Head of Strategy at CytomX Therapeutics, Inc..
  - Action: terminated
  - Role: Senior Vice President, Chief Business Officer, and Head of Strategy
  source text: On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312525019257/0001193125-25-019257-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.